AbbVie completed its $63 billion acquisition of Allergan after FTC approval requiring divestiture of digestive drug brazikumab to resolve antitrust concerns. The merger created a pharmaceutical giant with combined 2019 revenues of $48 billion and a diversified portfolio spanning immunology, …
AbbVieAllerganFederal Trade Commissionantitrustconsolidationmergerpharmaceutical-industryregulatory-capture+3 more
AbbVie reached settlement agreements with eight biosimilar manufacturers that allowed immediate biosimilar competition in Europe starting October 16, 2018, but delayed all US market entry until 2023—seven years after Humira’s original patent expired in December 2016. The settlements ended …
AbbVieAmgenSamsung BioepisMylanBoehringer Ingelheim+3 morepharmaceutical-industrypatent-abusedrug-pricinghealthcareevergreening+2 more
Johns Hopkins researchers published findings demonstrating that pharmaceutical companies were systematically gaming the 1983 Orphan Drug Act by obtaining orphan drug designations—intended for treatments of rare diseases affecting fewer than 200,000 Americans—for blockbuster drugs generating billions …
Johns Hopkins UniversityFDAAbbVieRocheJohnson & Johnson+4 morepharmaceutical-industryregulatory-capturetax-avoidancedrug-pricinghealthcare+2 more